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1. Introduction
Radiation therapy is used widely for the treatment of diffuse primary and metastatic brain
tumors [1]. Especially for nasopharyngeal carcinoma (NPC), the most common type of cancer
in southern China, radiation therapy is the first-choice treatment and sometimes the only
effective management of the disease. As many as 200,000 patients receive partial large-field or
whole-brain irradiation every year, and the population of long-term cancer survivors keeps
on growing. During treatment, however, some healthy brain tissues are also exposed to the
radiation inevitably, and consequently many patients may experience neurological symptoms
associated with damage to these healthy tissues after radiotherapy. Some of these symptoms
may even last for months or years. This is known as acute and chronic radiation-induced brain
injury (RIBI), also known as radiation encephalopathy (RE). Approximately 100,000 primary
and metastatic brain tumor patients each year in the US survive long enough (>6 months) to
experience RIBI [2]. For example, the incidence of RIBI for patients with NPC in Guangdong
province is up to 3 per 100,000, to our knowledge, 40 times higher than the world average and
is the most common one among head and neck tumor. RIBI includes a series of clinical
manifestations, such as focal neurological deficits, secondary epilepsy, mental and behavioural
disorders, elevated intracranial pressure, and the progressive deterioration of the hippocam‐
pal-associated learning and memory functions [3],which can be especially devastating to
patients and caregivers.
The American Cancer Society center (ACS) stresses that in order to maximize the quality of
life for tumor patients after radiotherapy, the future research should focus on preventing and
curing complications of cancer therapy. RIBI, a common and devastating complication of
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radiotherapy for brain tumor, is now emerging as a major health problem in the treatment of
brain tumor.
2. Pathogenesis
Based on the time between onset of clinical expression and radiation therapy administration,
RIBI has been classified into acute, early delayed, and late delayed injury, which was first
reported by Sheline [4]. Acute brain injury occurs during and/or in days to weeks after
irradiation. Early delayed brain injury occurs 6–12 weeks post-irradiation [5], while some other
researchers consider this time course is 1-6 months [6]. Although both of these early injuries
can result in severe reactions, they rarely occur and normally resolve spontaneously or
reversible after short-term treatment. In contrast, late delayed brain injury, usually developing
6 months post-irradiation, which is most significantly higher than that of acute and early
delayed RIBI, have been viewed as irreversible and progressive continuously due to the
pathogenesis [7].
The knowledge of the mechanisms underlying the RIBI following irradiation is the basis for
improving the therapies and prophylaxes, but it is not wholly clear.
The most direct affecting risk of RIBI is the radiation doses, fractionation schemes, and
adjuvant treatments. [8, 9] Liu Y and Xiao S et al. found that single-dose irradiation at 10Gy
failed to induce any significant effects in young male rats whereas an exposure at 20 to 40Gy
induced acute brain injury at both cognitive and pathologic levels. [10] Zhou H. and Liu Z. et
al. reported that fractionated irradiation of 20 to 40Gy could also induce acute brain injury in
young rats which indicated the role of fractionation schemes. [11] Furthermore, Ruben JD et
al. not only demonstrated the risk of radiation dose and fraction size, but the subsequent
administration of chemotherapy as well. [9]
In general, ionizing radiation can cause RIBI by either direct or indirect way and it is likely
that the successful unraveling of this puzzle will not come true without the basic study of
subtle molecular, cellular, or microanatomic changes in the brain. Hereon, we will discuss the
pathogenesis of RIBI from oxidative stress, nonspecific inflammation, blood brain barrier(BBB)
disruption as well as apoptosis and inhibition of neurogenesis which act alone or accompanied.
2.1. Oxidative stress
It is reported that in the unilaterally irradiated animals, irradiated hemispheres showed
similarly significant changes in oxygenation compared to unirradiated controls. [12]
Due to radiation therapy, the microglia is activated and immune cells begin to infiltrate the
brain. These cells then produce reactive oxygen species (ROS) whose production and detoxi‐
fication are normal physiological processes. Nevertheless, an imbalance between ROS
production and ROS removal may lead to oxidative stress [13, 14].Several components of ROS
can cause damage to cardinal cellular components, such as lipids, proteins, and DNA, initiating
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor144
subsequent cell death via necrosis or apoptosis [15]. Thus, ROS can be contributed to neuronal
toxicity and implicated in both acute injury and chronic neuropathological conditions [16].
Many related molecules have been reported. Jun showed hydrogen peroxide (H2O2)-induced
oxidative stress and apoptosis in HT22 cells accompany by up-regulated expression of p-ERK
1/2, p-JNK, and p-P38 [13]. What is more, the effectiveness of edaravone(a new agent of
ROSscavenger), peroxisome proliferator-activated receptor (PPAR) gamma agonists, and
antioxidants/antioxidant enzymes in preventing or mitigating the severity of RIBI also
provided an evidence of the oxidative stress. [13, 17]
2.2. Nonspecific inflammation
Irradiation can caused an acute endothelial cell apoptosis which lead to BBB breakdown,
chronic hypoxia and peritumoral tissue edema. [18] Meanwhile, nonspecific inflammation
cascades which further promote the microenvironmental changes, radiation necrosis, and
neurogenesis inhibition was activated [19].
Radiation could induce astrocytes proliferation and secrete a great quantity of pro-
inflammatory mediators after irradiation, which may aid the infiltration of leukocytes into the
brain via blood-brain barrier (BBB) breakdown [20, 21]. Microglias could also be activated by
quantity of irradiation through rapid proliferation, as well as increased production of ROS and
other cytokines which are involved in mediating neuroinflammation [22].
Plenty of experiments have found up-regulation of pro-inflammatory transcription factors
after irradiation which constituted the evidence of nonspecific inflammation cascades in the
process of RIBI. Moore, A. H. suggest that radiation-induced changes in vascular permeability
are dependent on cyclooxygenase 2 (COX2), one of two isoforms of the obligate enzyme in
prostanoid synthesis and the principal target of non-steroid anti-inflammatory drugs activity.
[23] Lee et al. found mRNA and protein of pro-inflammatory mediators including tumour
necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattrac‐
tant protein-1 (MCP-1) activated significantly in regions isolated from irradiated in rat brain.
[24] TNF-alpha is thought to be able to up-regulate other pro-inflammatory cytokines and
increase BBB permeability, increase leukocyte adhesion, activate astrocytes, and induce
endothelial apoptosis. And the further research demonstrated that anti-inflammation factor
(TNF-alpha) successfully inhibited radiation-induced effects in the local as well as abscopal
region in the brain. [12] Peroxisome proliferator-activated receptor (PPAR) gamma is ligand-
activated transcription factor that belong to the steroid/thyroid hormone nuclear receptor
superfamily. And the effectiveness of PPAR-gamma agonists is also a strong demonstration
of nonspecific inflammation. [25]
What is more, radiation could induce the loss of oligodendrocyte type-2 astrocyte (O-2A)
progenitor cell, the most radiosensitive type of glial cell, which leads to transient demyelina‐
tion soon after irradiation. Since all the brain gliocytes including oligodendrocyte, astrocytes
and microglia would participate in the radioactive damage process in different ways and RIBI
is predominated by white matter necrosis and demyelination, the pathological mechanism is
well known as Gliocyte Hypothesis. However, there is conflicting conclusion that the targeted
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anti-inflammatory agent has no effect on gliocytes, but can still ameliorate RIBI [26]. Conse‐
quently, pathological mechanism of RIBI cannot be explained so simply by the Gliocyte
Hypothesis despite the large amount of evidence supporting this hypothesis.
Due to the synergistic effect of oxidative stress and nonspecific inflammation after irradiation,
endothelial cell nuclear, blood vessel density, and blood vessel length are vulnerable to have
a reduction. The vascular damage can result in brain ischemia and even white matter necrosis.
[7]. All of this elicited the Vascular Hypothesis. Paradoxically, radiation-induced necrosis has
also been reported in the absence of vascular changes [27]. In addition, the PPARγ agonist,
pioglitazone, and the ACE inhibitor, ramipril, which are believed to prevent RIBI in the rat do
not reverse the reduction in vascular density and length that occurs after fWBI [28, 29].
Therefore, RIBI cannot be completely explained by any single cell or tissue despite a host of
evidence supporting these hypotheses. It is supposed to occur and develop due to active
interactions between the multiple cells. These participating cells are considered to play a
synergistic rather than initial role in the radiation brain injury [30].
2.3. Blood Brain Barrier(BBB) disruption
A number of data from laboratory animals has demonstrated acute BBB disruption which was
initiated by apoptosis of endothelial cells and mediated by the ASMase pathway after
irradiation [18]. As a result, change of BBB permeability has been thought to be the most
sensitive and reliable index for detection of early RIBI. [31] Breakdown of the BBB may also
enhance the effectiveness of chemotherapeutic agents, with the unintended consequence of
contributing to injury of the peritumoral tissue. Liu Y. and Xiao S. et al. found that a single-
dose exposure at 20 to 40 Gy induced acute brain injury at cognitive is more or less accompa‐
nied with increased brain water content and deteriorated BBB function, though mild
histopathologic alternations were only noticed in the 40-Gy-irradiated rats at 20 days. [10]
Zhou H. and Liu Z. et al. reported disrupted BBB permeability was detected after fractionated
irradiation of 20 to 40Gy in young rats and thus proved that the change in BBB permeability
could be one of the most sensitive and reliable indices of fractionated-radiation-induced acute
RIBI. [11] Besides, increased astrogliosis in the hippocampus could be detected at 4 weeks'
postirradiation for 40-Gy group.
2.4. Apoptosis and neurogenesis inhibition
The pathogenesis of RIBI may also relate to the process of neuronal apoptosis and inhibition
of neurogenesis.
Even gray matter contains neuronal cell bodies which is quite oxygen-dependent, neurons
have been considered radioresistant since they could no longer divide. However, it is reported
that apoptosis occurs in the young adult rat brain after ionizing irradiation and recent studies
also demonstrated that there exists direct radiation-induced damage to hippocampal neurons
with associated cognitive decline. The hippocampus consists of the DG, CA3, and CA1 regions.
Irradiating the hippocampus resulted in an increase in apoptosis in the subgranular zone of
the DG which are capable of both self-renewal and generating neurons, astrocytes, and
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oligodendrocytes [32, 33]. And blocking neurogenesis which was associated with alterations
of microenvironment including disruption of the microvascular angiogenesis and increase in
the number and activation status of microglia within the neurogenic zone can contribute to
the deleterious side effects of radiation treatment. [14]
Neurogenesis is also related to inflammation for the reason that anti-inflammatory drug was
proved to be capable of restoring and augments neurogenesis after cranial irradiation.
[19]However, these changes could also be observed in the absence of demyelination, blood
vessel density alternation and inflammatory cellular infiltration by a doses of ≤2 Gy that fail
to produce these changes [34].
3. Clinical characteristics of RIBI
3.1. Latency
The latency of RIBI exists a long time span. Chandler reported the time interval between the
end of radiotherapy to the onset of RIBI was 1 month to 16 years [35]. JY Qin et al. documented
the latency of RIBI was 3 months to 38 months, median time of which was 21.7 months [36].
We collected data of 130 NPC cases who suffered RIBI post radiotherapy, the latency of them
underwent a large time span from 0 to 32 years, the mean time was about 6 years [37].
Therefore, being focus on the mechanism research to get early differentiation, diagnosis,
explore therapeutic strategies of late delayed RIBI become more and more urgent.
3.2. Clinical features and classification
Acute effects occur during and/or shortly after the radiation exposure and are characterized
by symptoms of fatigue, dizziness, and signs of increased intracranial pressure. The acute
effects are considered to be secondary to edema and disruption of the BBB. Early delayed
effects of post-irradiation and usually show reversible symptoms generalized weakness and
somnolence, partly resulting from a transient demyelination. It is, however, the late delayed
effects that may lead to severe irreversible neurological consequences.
According to the site of involvement and corresponding clinical manifestations, the subtypes
of RIBI were divided into cerebellum type, brain stem and cranial type, cerebellum type and
mixed type.
3.2.1. Cerebral hemisphere type
Focal delivery of one large radiation fraction during radiotherapy can lead to focal injury of
the brain adjacent to the irradiated lesion [38].Clinically, patients present with focal neuro‐
logical deficits, which are often accompanied by focal increased intracranial pressure.
The most common and serious delayed complication of cerebral radiotherapy is cognitive
dysfunction. Take NPC for example, since inferior temporal lobes inevitably expose to the
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radiation, the prominent and earliest seen symptom of RIBI is distinctive cognitive impair‐
ment. Recently, Hsiao demonstrated that nasopharyngeal cancer patients treated with
intensity-modulated radiotherapy (IMRT) had a worse cognitive outcome if >10% of their
temporal lobe volume received a total fractionated dose of >60 Gy than patients who received
< 60 Gy [39]. The feature of cognitive impairment is different from those with Alzheimer’s
disease, it is characterized by decreased verbal memory, spatial memory, attention, novel
problem-solving ability, and even executive function. Patients usually accompanied with
negative emotions including depression, anxiety as well as somatization. Mental disorders
such as stupor state, hallucinations and delusions could also be observed as the injury
progresses [20].
It should be noted that significant cognitive impairment can be seen in the absence of radio‐
graphic or clinical evidence of demyelination or white matter necrosis after irradiation [40].
Therefore, conducting cognitive evaluations shortly post-irradiation at regular intervals is
becoming more and more important. Once cognitive decline is detected, no matter whether
there is imaging findings of brain lesions, prophylactic treatment should be given to the
patients immediately. The mini-mental status examination (MMSE), a test to assess global
cognitive function, is relatively insensitive to radiation-induced cognitive impairment [39,
41]. As the cognitive domains that are most affected by brain irradiation is distinct from the
common causes of dementia such as Alzheimer's disease and vascular dementia, current
Radiation Therapy Oncology Group (RTOG) study has established a series of tests that focuses
on the cognitive domains affected by brain irradiation, such as Dutch adult reading test for
assessing intelligence, vline bisection test for perception, visual verbal learning test for memory
and stroop color word test for executive function [42]. The Montreal cognitive assessment
(MoCA) is used to assess different cognitive domains including attention and concentration,
executive functions, memory, language, visuoconstructional skills, conceptual thinking,
calculations, and orientation. Sensitivity and specificity of MoCA application in radiation-
induced cognitive impairment has not been reported.
Another most common injury after radiotherapy is unilateral or/and bilateral temporal lobe
edema which might elevate intracranial pressure. If the pathogenesis develops persistently,
the area of edema could expand to the parietal lobes and then cause rapidly deteriorating
clinical course. Signs of increased intracranial pressure such as headache, nausea and vomiting
would get worse progressively. Severe cerebral edema could result in compression of cerebral
peduncle and cerebral hernia, which would lead to hemiplegia and even to death. Once that
occurs, surgical treatment will be needed. Moreover, cerebral edema could at last get lique‐
factive necrosis with formation of cystic spaces. Figure.1
3.2.2. Brain stem and cranial type
It has been reported that each pair of cranial nerve could get involved in injury after irradiation
in NPC patients [43]. Due to the irradiation fields mainly cover the lower part of brain stem,
the last four cranial nerves, glossopharyngeal nerve, vagus nerve, accessory nerve and
hypoglossal nerve, were commonly affected and leading to corresponding clinical manifesta‐
tions, such as atrophy of tongue muscle, dysphagia, dysphonia and dysdipsia. Severe bulbar
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palsy may significantly decrease the life quality of patients and sometime is fatal caused by
subsequent lung infection and/or malnutrition [43]. And the frequency of upper cranial nerve
injury increased greatly if the patients have to conduct re-radiotherapy.
Some other common involved cranial nerve is cochleovestibular nerve caused by not only
direct effect of irradiation to the nerve but also the indirect effect of the inner ear damage after
radiotherapy such as secretory otitis media or even intractable suppurative otitis media. The
prime symptoms of disorders of the cochleovestibular nerve are vertigo, tinnitus and pain.
Irreversible hearing loss caused by nerve deafness, conduction deafness and mixed deafness
will happen in the end [43].
Radiation-induced optic neuropathy (RION) is a rare but usually devastating side effect of
radiotherapy for NPC. The most frequent clinical symptoms of RION typically present with
sudden, painless, irreversible vision loss in one or both eyes after radiotherapy, and occur most
commonly from 3 months to more than 9 years after radiotherapy. Liu et al. reported RION in
NPC patients [44]. Ophthalmologic examinations showed flake bleeding in the retina, optic
nerve atrophy and cotton-wool spots. T1-weighted enhanced MRI images showed enhance‐
ment of the optic nerve and optic chiasm in six cases.
One more severe clinical manifestation is syncope. Damage to descending sympathetic nerve
fibers, which anatomically run along the brain stem, may result in hazardous syncope as well
Figure 1. Cerebral edema and atrophy of a 39-year-old female cerebral hemangioma patient. 8 years after the treatment
of gamma knife. Lumps-like abnormal signal was shown in the right-basolateral region, heterogeneous high signal
was shown on T2W, surrounded by low signal, a large fingerlike high signal of the white matter around lesions on
T2W. Cerebral gyrus of the frontal and parietal lobe narrow and cerebral sulcus widen which is the sign of cerebral
atrophy. A.T2WI B. T2WI C.FLARE D.FLARE
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as Horner syndrome. Crossed hemiplegia might also occur when pyramidal tract is involved
simultaneously [43].
3.2.3. Cerebellum type
It is the least common type of RIBI. Damage to cerebellum results in edema of cerebellar
hemisphere and leads to symptoms such as vertigo, stumbling, ataxia and other discomfort.
The injury to cerebellum has the same prognosis as that in cerebral hemisphere and eventually
develop into the tonsillar hernia.
3.2.4. Mixed type
It is a combination of two or more subtypes mentioned above.
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Figure 2. A. Fundus examination in radiation-induced optic neuropathy: ocular fundus showing flame-shaped and dot
hemorrhage (bottom row, h, arrow) and cotton-wool spots (top row, bottom row, p). B. Axial MRI of three patients
showing: (a, b) tortuous optic nerve with blurring of edges, and (b) optic nerve atrophy; (b, c) T1-weighted enhanced
MRI showing enhancement of the optic nerves and optic chiasm.
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4. Value of neuroimaging in RIBI diagnosis
Neuroimaging, including computed tomography (CT), magnetic resonance imaging (MRI)
especially neurological functional imaging technology, provide valuable information in early
diagnosis and differential diagnosis of RIBI. In this paragraph, we will provide a variety of
neuroimaging information to readers. Including not only traditional CT/MRI imaging, but also
proton magnetic resonance spectroscopy (MRS) and iffusion tensor imaging (DTI).
4.1. Computed Tomography (CT)
CT foundings of focal radiation brain edema and necrosis are generally low density, while the
affected white matter is usually symmetric and exhibit no enhancement or irregular peripheral
enhancement with contrast material. The brain lesions would range from small foci near the
frontal or occipital horns to a confluent band extending from the ventricles to the corticome‐
dullary junction. Figure.3
 
Figure 3. CT founding of a 59-year-old male patient with NPC after radiotherapy for over 10 years. A. cystic liquefac‐
tive necrosis of the right temporal lobe with edema around lesions. B. no enhancement.
4.2. Magnetic resonance Imaging (MRI)
MRI is definitely more valuable for the diagnosis of RIBI than CT. The appearence of finger
like edema and focal necrosis which shows low signal intensity on T1WI and high signal on
T2WI are typical feature of MR imaging in patients with RIBI. Ringlike or irregular enhance‐
ment in the bilateral temporal lobes are also frequently seen on T1WI enhanced MR imaging
while haemorrhage with heterogeneous signals is relative rare. (Figure.4)These findings on
conventional MRI technology are not specific and insufficient to distinguish RIBI from tumor
recurrence or other diseases. Thus various new technologies of MRI are employed to make up
for this shortcoming.
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Figure 4. Radiation necrosis and edema. MRI performed 8 years after radiotherapy of one 54-years-old male patient
with NPC. Necrosis of right-temporal and right-parietal lobe shows low signal intensity on T1WI and high signal on
T2WI with enhanced boundary. Edema of the left-temporal lobe shows finger like low signal intensity on T1WI and
high signal on T2WI with non-enhanced boundary. A. T2WI; B. T1WI; C.T1WI+C
4.3. Proton magnetic Resonance Spectroscopy (MRS)
MRS is used to display metabolite changes in normal appearing white matter after fWBI in the
brain. Brain metabolites are quantified including choline(Cho), creatine(Cr), glutamate(Glu),
glutamine(Gln), N-acetyl-aspartate (NAA) and lactate. It is reported that NAA, Cr and Cho
change regularly from the center of the visible lesions. In the liquefaction and necrosis foci,
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NAA, Cr and Cho are nearly absent. In the visible lesions, the levels of NAA increase slightly,
while the contents of Cr and Cho decreased obviously. Certain extent away from the visible
lesions, the contents of NAA decrease and the levels of Cr and Cho increase. Farther away
from the lesions, the levels of the three substances gradually become normal. Consequently
the ratios of NAA/Cr and Cho/Cr alter from periphery to the lesion, decrease from a value
above 1 to one less than 1. A ratio of NAA/Cr and Cho/Cr less than 1 may be highly indicative
of nerve and cell structure damage in the brain tissue [45, 46]. In view of this, MRS is supposed
to indentify a larger area of abnormal metabolism in RIBI than visible lesion in MRI, which
makes it possible to detect RIBI in early stage.
4.4. Diffusion Tensor Imaging (DTI)
DTI is a novel way to assess tissue microstructure by measuring the diffusion of water
molecules in three-dimensional (3D) space. It is often applied to distinguish demyelination
from axonal injury within white matter bundle. In a DTI study of childhood survivors after
fWBI for acute lymphoblastic leukemia, fractional anisotropy (FA) decreases significantly in
the frontal and parietal lobes related to declines in intelligence quotient [47]. In another study
of adult survivors post fWBI for acute leukemia, FA values reduced obviously in normal
appearing cerebral white matter of the temporal lobe, hippocampus, and thalamus [48]. DTI
is thought to be a promising technique to detect early changes in white matter integrity before
image evidence of radiation-induced demyelination or necrosis. However, the application of
DTI to RIBI is just in its infancy. Figure.5
Figure 5. Delayed RIBI of bilateral temporal. Edema is obvious. Isotropic map shows high signal in the lesion area
which is wider than FLAIR. Anisotropic map shows low signal in the bilateral temporal lobe and white matter fiber of
the normal temporal lobe shows high signal and blurred.
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5. Treatment strategies
Up to now, there has been no proven effective treatment to reverse or terminate the patho‐
genesis brain irradiation injury, which could be particularly devastating to patients and
caregivers since the exact mechanisms of RIBI is unclear. Potential therapeutic strategies to
prevent RIBI will be discussed in this part.
5.1. Glucocorticoids
Glucocorticoids play a vital role in the comprehensive therapy for RIBI. A large number of
experimental and clinical studies have confirmed its polyvalent efficacy of narrowing lesions,
relieving symptoms as well as improving their prognosis by counteracting the radiation-
induced vascular endothelial damage and inflammatory cascade [49]. Dispute still remains
over the opportunity, dose and course of glucocorticoid therapy. Many a researchers recom‐
mend maintenance therapy with regular dose for more than 3 months while some others affirm
the effect of early large dosage of corticosteroids for shorter periods [49]. Some patients may
be weaned off after a period of symptomatic exacerbation while in some cases symptoms can
return after steroid cessation and lead to necessitating long-term steroid use. Unfortunately,
the prolonged systemic administration will result in immunosupression, psychiatric distru‐
bances, myopathy and sequelae of endocrinologic compromise such as hypertension, diabetes
mellitus, osteoporosis, weight changes and thickening of facial subcutis [49].
5.2. Antiplatelets and anticoagulation
Radiation induced vascular endothelial injury may lead to subsequent mural thrombosis, thus
antiplatelets may play a crucial part in preventing the RIBI. Currently exsisted antiplatelet
drugs mainly include cyclooxygenase(COX) inhibitors and adenosine diphosphate (ADP)
receptor antagonists. Phosphodiesterase inhibitors, a new type of antiplatelet agents, have
been proved to be protective for intravascular thrombosis after radiation [2].
Another kind of drug to control thrombosis is anticoagulation drugs. It’s reported that the use
of heparin and warfarin lead to partial recovery of function in five of eight patients with
cerebral radiation necrosis when they were proved to be unresponsive to steroid therapy [50].
One case concerning a patient experienced a recurrence of symptoms following discontinua‐
tion of anticoagulation therapy and was reversed again by resuming anticoagulation treatment
[50] demonstrated the limited success of anticoagulation drug. However, this treatment need
to be validated in larger trials before clinical application.
5.3. Reactive Oxygen Species (ROS) scavengers
Edaravone, a new agent of ROS scavenger, has been verified effective in reducing the vascular
endothelial cell injury, inhibiting brain encephaledema and preventing neuronal cell necrosis
[51]. Our clinical trails on 42 NPC patients suffered RIBI has demonstrated that efficiency
(50.0%) and total efficiency (88.9%) in the edaravone administration group were significantly
higher than that in the contrast group (14.3% and 42.9%). After a 4-week treatment, the lesion
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volume on MRI was smaller than before in edaravone group, and the scores of 6 domains, 19
aspects and the overall quality of life in edaravone group were significantly higher than those
in non-edaravone group [52]. However, ROS scavengers have received not so much attention
because they are likely to protect brain tumors to the same extent as they protect normal brain
[2]. Another antioxidant and radioprotective drug is vitamin E. The administration of Vitamin
E significantly reduced the severity of radiation-induced brain damages and increased the
activity of superoxide dismutase and catalase enzymes in the brain. [53]
5.4. Refactoring microcirculation
The butyl-phthalide, a neotype of drugs reforming the microcirculation, has multiple effects
of increasing the perfusion in the ischemia area, protecting the mitochondria from hypoxic
injury, and also reducing neuronal apoptosis. Human urinary kallidinogenase for injection,
another new agent of this type, may be instrumental in vasodilation of brain blood vessels,
increasing haemoglobin in the cerebral blood flow, and also improving glucose metabolism in
ischemic brain tissues [54].
5.5. Reconstructing the nerve function
Radiation injury could destroy the nerve structure and then lead to loss of neuron function.
Therefore neural plasticity is thought to play a vital role in the comprehensive treatment for
RIBI. As our data from animals and humans shows that gangliosides is helpful in promoting
the recovery of nerve function in lesioned brain, spinal cord and also peripheral nerve. A host
of in vivo and in vitro studies also demonstrated that neurotrophic factors are neuroprotective
in radiation-induced nouropathy. Curative effect has been proved in patients with temporal
lobe injury after two-month injection with mouse nerve growth factor, both MR imaging and
cognitive function of them were improved significantly [55].
5.6. Renin–Angiotensin System(RAS) inhibitors
The RAS has been viewed as a classical systemic hormonal system. Recently several intra-
organ RAS including a brain RAS have been identified. The brain RAS is involved in modu‐
lation of the BBB, stress, memory, and cognition. Both angiotensin-converting enzyme
inhibitors (ACEI) and angiotensin receptor blockers (ARB) have been proved effective in
treating experimental radiation nephropathy and pneumopathy [56, 57]. As for their effect on
encephalopathy, studies of Jenrow et al. (2010) show that administration of the ACEI, ramipril
has modest protection against WBI-induced decreases in neurogenesis, but did not modulate
radiation-induced neuroinflammation while other report has different conclusion with a
different timing of chronic administration of theramipril and/or the response after single or
fractionated doses on rodent [58, 59]. Whether all of the drug mentioned above can be useful
for the patient of RIBI remains to be further elucidated.
5.7. Symptomatic treatment
Dehydration medicine such as mannitol and albumin should be given to patients with high
cranial pressure. Antiepileptic drugs (AED) should be chosen according to the forms of
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epilepsy seizures. Serotonin (5-HT) reuptake inhibitors and psychological therapies might be
preferred when anxiety and depression are the cardinal symptoms.
It should be mentioned that there has been no known preventive medications for radiation-
induced cognitive impairment in humans, although several pharmacologic agents have been
assessed for symptomatic management [2]. The Wake Forest Community Clinical Oncology
Program Research Base completed a phase II study using 10mg/day of a cholinesterase
inhibitor namely donepezil, which showed significant improvement in energy level, mood,
and cognitive function in radiation-induced brain injury survivors [60]. Memantine, an NMDA
receptor antagonist being able to block ischemia-induced NMDA excitation, was proven to be
effective in vascular dementia. Thus it is supposed to be conducive to radiation-induced
cognitive impairment if radiation-induced ischemia occurs after fWBI. Other potential
pharmacological mediators based on preclinical researches suggesting that anti-inflammatory
agents could prevent or ameliorate radiation-induced cognitive function. As for anti-inflam‐
matory peroxisome proliferator-activated PPARγ agonists, researchers have found some
evidence that they maight prevent/ameliorate radiation-induced cognitive impairment when
given for only a few weeks after fWBI on rodent [61].
5.8. Surgical management
Surgical resection can be considered when the patient’s necrosis are symptomatic and have no
take a turn for the better after medical treatments. For example, when suffering from large
area-cerebral edema, and the condition progressively exacerbated active medications although
has been given, patients should also be recommended to surgically remove the focal brain
lesions in time when the location is in a region that is surgically accessible. During this process,
the surgeon should avoid incurring additional significant neurologic morbidity. [85]
5.9. Neural Stem Cells(NSCs) therapies
In addition to drug therapeutics, there has been increased interest in the use of various NSCs
therapies. Pioneering researchers directly inject NSCs into rodent brains after WBI and found
it partially restores cognitive function [62, 63]. Interestingly, these NSCs not only differentiate
into neurons, but also oligodendrocytes, astrocytes and endothelial cells that can alter the
hippocampal microenvironment [63]. However, the use of exercise or NSCs transplantation
to prevent/ameliorate RIBI in humans will require considerably more research before it can be
translated to the clinic.
5.10. Organ-sparing approach
To date, one of the strategies to prevent RIBI in the clinic involves organ-sparing approach
which is based on neuroanatomical target theory. Technology has evolved to potentially allow
for selective avoidance of the regions of adult neurogenesis, including the hippocampus and
neural stem cell niche in the periventricular regions. With the help of advanced radiation
techniques, such as 3D conformal image guidance [64], inverse-planned intensity modulated
radiotherapy (IMRT) [65] and proton beam radiotherapy [66], it is expected to reduce the
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occurrence of RIBI by limiting the dose to critical organs and possibly increasing locoregional
tumor control. [67]
5.11. Anti-VEGF antibody
As is mentioned above, the necrosis is partly due to increasing capillary permeability which
is caused by cytokine release leading to extracellular edema. The edema is the most common
pathology of RIBI is just sustained by endothelial dysfunction, tissue hypoxia as well as
subsequent necrosis. Consequently, it is a logical option to block the vascular endothelial
growth factor (VEGF) at an early stage to reduce the development of radiation necrosis and
thus decrease the vascular permeability. After the patient with radiation-induced necrosis was
treated with an anti-VEGF antibody (bevacizumab), the improvement neurologic signs and
symptoms in accordance with the decrease in T1-weighted fluid-attenuated inversion recovery
signals put bevacizumab as a treatment direction for patients with RIBI [68].
5.12. Hyperbaric Oxygen Treatment (HBOT)
HBOT is proven to be able to stimulate angiogenesis and restore the regional blood supply by
reaching the goal of increasing parenchymal oxygen concentration. HBOT treatment has been
demonstrated to be beneficial in pediatric patients with radiation necrosis [69]and in smaller
series and case reports [70, 71]. However, Jun L et al. reported that HBOT treatment did not
reduce visual loss or blindness in patients with RION [44]. As single institution studies vary
widely due to patient selection bias, it would be necessary to conduct more randomized trials
to delineate the true benefit of HBOT. [72]
6. Problems and prospects
Although a great many treatment strategies have eliminated acute and early delayed brain
injury as well as most delayed demyelination and white matter necrosis, radiotherapy is still
carries a risk of RIBI which may seriously affect the life quality of survivors. This risk is further
exacerbated while the patient need to use chemotherapeutic agents at the same time [2].
To get more knowledge about the mechanism of RIBI is the key to the solution. Although many
theories have been proposed, it is likely that the pathogenesis in long term survivors of various
tumors like small cell lung cancer, NPC, low-grade glioma, non-parenchymal tumors, primary
brain tumors and metastatic brain tumors are different just because they were treated differ‐
ently. There is not a solely theory that can be used to fully answer this question.
As a result, it is imperative to detect the pathological change non-invasively as early as possible.
However, there still a lot of difficulties which need to be solved in clinical practice. It is explicit
that the most important issue is to differentiate radiation necrosis and tumor progression.
Fortunately, there are multiple radiological and nuclear medicine techniques available to help
us even these anatomic and metabolic imaging techniques all have inherent limitations in
sensitivity and specificity.
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Researchers all over the world have tried hard but have had only modest success in modulating
RIBI to date. However, the future looks promising since we have attached importance to RIBI
and find some innovative treatments such as the NECs or anti-VEGF therapy which can be the
alternative offer [72].
Over the next decade, we will continue paying more attention to the investigation that how
radiation-induced brain injury develops and how it can be treated [2].
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